Bluebird Bio‘s work has been at the epicenter of gene therapy, working on a litany of fields that intersect with the work of the industry’s top firms. This slide from its J.P. Morgan presentation this week illustrates that quite nicely:
Awesome slide shows what a broad range of technologies $BLUE is a player in. #JPM15 pic.twitter.com/ket7h5tsjO
— Brad Loncar (@bradloncar) January 14, 2015
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
The company’s stock has just killed it in the past year – from $BLUE trading around $17 per share a year ago to hitting highs above $100 this year.
Biopharma Dive wrote of the #JPM15 presentation:
It’s one of the hottest biotechs in the world, and it’s planning on presenting major clinical data by the end of the year. bluebird bio CEO Nick Leschly told JPM15 attendees that the company will unveil data for its ambitious sickle cell gene therapy platform LentiGlobin in 2015.
Worth watching, if you haven’t, is CEO Nick Leschly’s TEDxBoston talk from a couple years ago.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.